Literature DB >> 6456692

Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

M Y Khan, Y Siddiqui, R P Gruninger.   

Abstract

The in vitro activity of a new ora antimicrobial agent, Mk-0366 (AM-715), was compared with those of rosoxacin, ampicillin, erythromycin, and tetracycline against Neisseria gonorrhoeae. Mk-0366 was as active as rosoxacin and more active than the other three antimicrobial agents. It inhibited all isolates, regardless of beta-lactamase activity, at a concentration of 0.03 micrograms/ml.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6456692      PMCID： PMC181677          DOI： 10.1128/AAC.20.2.265

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  The susceptibility of Neisseria gonorrhoeae to cefoxitin sodium.

Authors:  I Phillips
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

2.  Penicillinase-producing Neisseria gonorrhoeae.

Authors:  C W Phillips; R D Aller; S N Cohen
Journal:  Lancet       Date:  1976-10-30       Impact factor: 79.321

3.  In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains.

Authors:  C N Baker; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

4.  Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae.

Authors:  S W Berg; M E Kilpatrick; W O Harrison; J A McCutchan
Journal:  N Engl J Med       Date:  1979-09-06       Impact factor: 91.245

5.  Clinical experience in the use of cefuroxime in gonorrhoea.

Authors:  W Fowler; G Rahim; J D Brown
Journal:  Br J Vener Dis       Date:  1978-12

6.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections.

Authors:  K Hirai; A Ito; Y Abe; S Suzue; T Irikura; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191
  7 in total
  23 in total

1.  Norfloxacin in the therapy of uncomplicated gonorrhea.

Authors:  B Romanowski; H Wood; J Draker; M C Tsianco
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  In vitro antimicrobial sensitivity of Neisseria gonorrhoeae from Rwanda.

Authors:  J Bogaerts; J Vandepitte; E Van Dyck; R Vanhoof; M Dekegel; P Piot
Journal:  Genitourin Med       Date:  1986-08

4.  In vitro activity of norfloxacin against Chlamydia trachomatis.

Authors:  H Meier-Ewert; G Weil; G Millott
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

5.  In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.

Authors:  M Peeters; E Van Dyck; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit.

Authors:  R W Darrell; S M Modak; C L Fox
Journal:  Trans Am Ophthalmol Soc       Date:  1984

7.  In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Authors:  J D Gay; D R DeYoung; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.

Authors:  F W Heessen; H L Muytjens
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.

Authors:  S Nakamura; N Kurobe; S Kashimoto; T Ohue; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.